Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection.

Littmann, Eric R; Lee, Jung-Jin; Denny, Joshua E; Alam, Zahidul; Maslanka, Jeffrey R; Zarin, Isma; Matsuda, Rina; Carter, Rebecca A et al. · Nat Commun · 2021

basic_science · Level V

Where this comes from

Abstract

Fecal microbiota transplantation (FMT) is a successful therapeutic strategy for treating recurrent Clostridioides difficile infection. Despite remarkable efficacy, implementation of FMT therapy is limited and the mechanism of action remains poorly understood. Here, we demonstrate a critical role for the immune system in supporting FMT using a murine C. difficile infection system. Following FMT, Rag1 heterozygote mice resolve C. difficile while littermate Rag1<sup>-/-</sup> mice fail to clear the infection. Targeted ablation of adaptive immune cell subsets reveal a necessary role for CD4<sup>+</sup> Foxp3<sup>+</sup> T-regulatory cells, but not B cells or CD8<sup>+</sup> T cells, in FMT-mediated resolution of C. difficile infection. FMT non-responsive mice exhibit exacerbated inflammation, impaired engraftment of the FMT bacterial community and failed restoration of commensal bacteria-derived secondary bile acid metabolites in the large intestine. These data demonstrate that the host's inflammatory immune status can limit the efficacy of microbiota-based therapeutics to treat C. difficile infection.

Medical subject headings